NBIX — Neurocrine Biosciences Share Price
Last trade - 00:00- $10.03bn
- $8.95bn
- $2.36bn
- 94
- 38
- 41
- 59
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 20.97 | ||
| PEG Ratio (f) | 0.83 | ||
| EPS Growth (f) | 33.55% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.87 | ||
| Price to Tang. Book | 3.93 | ||
| Price to Free Cashflow | 18 | ||
| Price to Sales | 4.26 | ||
| EV to EBITDA | 14.98 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 17.77% | ||
| Return on Equity | 14.16% | ||
| Operating Margin | 24.22% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,045.9 | 1,133.5 | 1,488.7 | 1,887.1 | 2,355.3 | 2,664.11 | 3,099.03 | 24.48% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +222.53 | -65.32 | +11.8 | +86.83 | -12.45 | +20.41 | +59.18 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
Directors
- William Rastetter NEC (73)
- Kevin Gorman CEO (62)
- Matthew Abernethy CFO (41)
- Julie Cooke CHO (55)
- Jude Onyia CSO
- Eric Benevich OTH (55)
- David Boyer OTH (42)
- Kyle Gano OTH (48)
- Dimitri Grigoriadis OTH (63)
- Malcolm Lloyd-Smith OTH (65)
- Eiry Roberts OTH (57)
- Darin Lippoldt SEC (55)
- Johanna Mercier DRC (51)
- Gary Lyons IND (69)
- George Morrow IND (69)
- Leslie Norwalk IND (55)
- Richard Pops IND (59)
- Shalini Sharp IND (44)
- Stephen Sherwin IND (72)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 20th, 1996
- Public Since
- May 23rd, 1996
- No. of Shareholders
- 39
- No. of Employees
- 1,800
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 98,938,234
- Address
- 6027 EDGEWOOD BEND COURT, SAN DIEGO, 92130
- Web
- https://www.neurocrine.com/
- Phone
- +1 8586177600
- Contact
- Todd Tushla
- Auditors
- Ernst & Young LLP
Latest News for NBIX
Upcoming Events for NBIX
Q1 2025 Neurocrine Biosciences Inc Earnings Release
Q1 2025 Neurocrine Biosciences Inc Earnings Call
Neurocrine Biosciences Inc Annual Shareholders Meeting
Neurocrine Biosciences Inc Annual Shareholders Meeting
Q2 2025 Neurocrine Biosciences Inc Earnings Release
Similar to NBIX
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 22:14 UTC, shares in Neurocrine Biosciences are trading at $101.38. This share price information is delayed by 15 minutes.
Shares in Neurocrine Biosciences last closed at $101.38 and the price had moved by -23.91% over the past 365 days. In terms of relative price strength the Neurocrine Biosciences share price has underperformed the S&P500 Index by -28.45% over the past year.
The overall consensus recommendation for Neurocrine Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreNeurocrine Biosciences does not currently pay a dividend.
Neurocrine Biosciences does not currently pay a dividend.
Neurocrine Biosciences does not currently pay a dividend.
To buy shares in Neurocrine Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $101.38, shares in Neurocrine Biosciences had a market capitalisation of $10.03bn.
Here are the trading details for Neurocrine Biosciences:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: NBIX
Based on an overall assessment of its quality, value and momentum Neurocrine Biosciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Neurocrine Biosciences is $158.92. That is 56.76% above the last closing price of $101.38.
Analysts covering Neurocrine Biosciences currently have a consensus Earnings Per Share (EPS) forecast of $4.11 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neurocrine Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -4.8%.
As of the last closing price of $101.38, shares in Neurocrine Biosciences were trading -20.22% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Neurocrine Biosciences PE ratio based on its reported earnings over the past 12 months is 20.97. The shares last closed at $101.38.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Neurocrine Biosciences' management team is headed by:
- William Rastetter - NEC
- Kevin Gorman - CEO
- Matthew Abernethy - CFO
- Julie Cooke - CHO
- Jude Onyia - CSO
- Eric Benevich - OTH
- David Boyer - OTH
- Kyle Gano - OTH
- Dimitri Grigoriadis - OTH
- Malcolm Lloyd-Smith - OTH
- Eiry Roberts - OTH
- Darin Lippoldt - SEC
- Johanna Mercier - DRC
- Gary Lyons - IND
- George Morrow - IND
- Leslie Norwalk - IND
- Richard Pops - IND
- Shalini Sharp - IND
- Stephen Sherwin - IND